Abstract:Microtubule affinity-regulating kinase 4 (MARK4) belongs to a family of kinases that are able to actively phosphorylate the neuronal microtubule-associate proteins (MAPs), such as tau, MAP2 and the ubiquitous MAP4. Abnormal changes in tubulin and the profiles of tau have been previously reported in the human brain and animal transmissible spongiform encephalopathies (TSEs), which may be associated with abnormal alterations of various cellular kinases. To elucidate the possible role of MARK4 in TSE pathogenesis, the MARK4 levels in the brain tissues of scrapie-infected rodents and human prion diseases were evaluated using western blotting and immunohistochemical assays. The results revealed that at terminal stages of the diseases, MARK4 levels in the brain tissues of the scrapie 263K-infected hamsters, 139A-infected mice and a case of Creutzfeldt-Jakob disease (CJD, G114V gCJD) correlated with amounts of PrP(Sc) deposits that were almost undetectable. On the other hand MARK4 signals were noticeable in the brain tissues of a fatal familial insomnia (FFI) patient without PrP(Sc). The reduction of MARK4 was closely related to the prolonged incubation times. These results could be reproduced in SK-N-SH and PC12 cell lines after being exposed to the synthetic peptide PrP106-126. Accordingly, the levels of phosphorylated tau at Ser262 (p-tau262) in cultured cells exposed to PrP106-126, or the ratios of p-tau262/total tau in the brain tissues of 263K-infected hamsters were also significantly decreased. According to our data there is a correlation between a TSE pathological-associated decline of MARK4 in the brain tissues with the deposits of PrP(Sc). Reduction of MARK4 will result in abnormalities of tau phosphorylation, and possibly induce further detachment of microtubules and hinder microtubule transportation.

Gain-of-function MARK4 variant associates with pediatric neurodevelopmental disorder and dysmorphism

Reduction of Protein Kinase MARK4 in the Brains of Experimental Scrapie Rodents and Human Prion Disease Correlates with Deposits of PrP(Sc).

Microtubule affinity-regulating kinase 4 with an Alzheimer's disease-related mutation promotes tau accumulation and exacerbates neurodegeneration

Microtubule affinity-regulating kinase 4: structure, function, and regulation

Therapeutic targeting of microtubule affinity‐regulating kinase 4 in cancer and neurodegenerative diseases

Syndromic craniosynostosis caused by a novel missense variant in MAP4K4: Expanding the genotype–phenotype relationship in RASopathies

Convergence on CaMK4: a key modulator of autism-associated signaling pathways in neurons

Heterozygous loss-of-function variants in DOCK4 cause neurodevelopmental delay and microcephaly

Microtubule‐affinity regulating kinase family members distinctively affect tau phosphorylation and promote its toxicity in a Drosophila model

Novel variants in AP4B1 cause spastic tetraplegia, moderate psychomotor development delay and febrile seizures in a Chinese patient: a case report

MARK2 variants cause autism spectrum disorder via the downregulation of WNT/β-catenin signaling pathway

Neuronal connectivity, behavioral, and transcriptional alterations associated with the loss of MARK2

Cdk5 increases MARK4 activity and augments pathological tau accumulation and toxicity through tau phosphorylation at Ser262.

Pathogenic variants in cause a neurodevelopmental syndrome via alteration of metabolic signaling

Abrogation of MAP4K4 protein function causes congenital anomalies in humans and zebrafish

Microtubule-associated Protein/Microtubule Affinity-regulating Kinase 4 (MARK4) Is a Negative Regulator of the Mammalian Target of Rapamycin Complex 1 (mTORC1)

Microtubule-affinity regulating kinase 4: A potential drug target for cancer therapy

De Novo Variants in MAPK8IP3 Cause Intellectual Disability with Variable Brain Anomalies

Monoallelic CRMP1 gene variants cause neurodevelopmental disorder

Inhibition of MARK4 by serotonin as an attractive therapeutic approach to combat Alzheimer's disease and neuroinflammation

Pathogenic variants in TMEM184B cause a neurodevelopmental syndrome via alteration of metabolic signaling